НовостиBenzingaCanaccord Genuity Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $75 Canaccord Genuity Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $75 Benzinga 2026.10.19 12:16 (GMT+0) Открыть на Benzinga Другие новости